These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38555726)

  • 21. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.
    Tunis SR; Maxwell LJ; Graham ID; Shea BJ; Beaton DE; Bingham CO; Brooks P; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2017 Oct; 44(10):1551-1559. PubMed ID: 28765256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.
    Aiyegbusi OL; di Ruffano LF; Retzer A; Newsome PN; Buckley CD; Calvert MJ
    Trials; 2022 Jan; 23(1):42. PubMed ID: 35033186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring communication as a core outcome in aphasia trials: Results of the ROMA-2 international core outcome set development meeting.
    Wallace SJ; Worrall L; Rose TA; Alyahya RSW; Babbitt E; Beeke S; de Beer C; Bose A; Bowen A; Brady MC; Breitenstein C; Bruehl S; Bryant L; Cheng BBY; Cherney LR; Conroy P; Copland DA; Croteau C; Cruice M; Dipper L; Hilari K; Howe T; Kelly H; Kiran S; Laska AC; Marshall J; Murray LL; Patterson J; Pearl G; Quinting J; Rochon E; Rose ML; Rubi-Fessen I; Sage K; Simmons-Mackie N; Visch-Brink E; Volkmer A; Webster J; Whitworth A; Dorze GL
    Int J Lang Commun Disord; 2023; 58(4):1017-1028. PubMed ID: 36583427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap.
    Leshem YA; Simpson EL; Apfelbacher C; Spuls PI; Thomas KS; Schmitt J; Howells L; Gerbens LAA; Jacobson ME; Katoh N; Williams HC
    Br J Dermatol; 2023 Nov; 189(6):710-718. PubMed ID: 37548315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inclusion of harm outcomes in core outcome sets requires careful consideration.
    Tay J; Robinson C; Blazeby J; Loke Y; Lowery A; Alkhaffaf B; Kirkham JJ
    J Clin Epidemiol; 2024 Oct; 174():111474. PubMed ID: 39038744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome Domains, Outcome Measures, and Characteristics of Randomized Controlled Trials Testing Nonsurgical Interventions for Osteoarthritis.
    Krsticevic M; Dosenovic S; Dimcea DA; Jedrzejewska D; Marques Lameirão AC; Almeida ES; Jelicic Kadic A; Jeric Kegalj M; Boric K; Puljak L
    J Rheumatol; 2020 Jan; 47(1):126-131. PubMed ID: 30877204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving core outcome set development: qualitative interviews with developers provided pointers to inform guidance.
    Gargon E; Williamson PR; Young B
    J Clin Epidemiol; 2017 Jun; 86():140-152. PubMed ID: 28495644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets.
    Maxwell LJ; Jones C; Bingham CO; Boers M; Boonen A; Choy E; Christensen R; Conaghan PG; D'Agostino MA; Doria AS; Grosskleg S; Hill CL; Hofstetter C; Horgan B; Kroon F; Leung YY; Mackie S; Meara A; Shea BJ; Simon LS; Touma Z; Tugwell P; Wells GA; Beaton DE
    Semin Arthritis Rheum; 2024 Jun; 66():152423. PubMed ID: 38460282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.
    Maxwell LJ; Beaton DE; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit M; Gossec L; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1014-1020. PubMed ID: 30770502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.
    Smith TO; Mansfield M; Hawker GA; Hunter DJ; March LM; Boers M; Shea BJ; Christensen R; Guillemin F; Terwee CB; Williamson PR; Roos EM; Loeser RF; Schnitzer TJ; Kloppenburg M; Neogi T; Ladel CH; Kalsi G; Kaiser U; Buttel TW; Ashford AE; Mobasheri A; Arden NK; Tennant A; Hochberg MC; de Wit M; Tugwell P; Conaghan PG
    J Rheumatol; 2019 Aug; 46(8):976-980. PubMed ID: 30824657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials.
    Décary S; de Wit M; Naye F; Barton JL; Fraenkel L; Li LC; Brooks P; Stacey D; Maxwell LJ; Campbell W; Hofstetter C; Voshaar M; Meara A; Christensen R; Boonen A; Suarez-Almazor ME; Meade T; March L; Jull JE; Alten R; Morgan EM; Stewart Hazlewood G; Barber CEH; Guillemin F; El-Miedany Y; Mittoo S; Robertson TW; Bartlett SJ; Singh JA; Mannion M; Nasef SI; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Berthelsen DB; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Beaton D; Shea B; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Lee RR; Umaefulam V; Monti S; Abaza N; Schultz G; Stones S; Gossec L; Nielsen SM; Cavallo S; Srinivasalu H; Constien D; Evans V; Tugwell P; Toupin-April K
    Semin Arthritis Rheum; 2024 Apr; 65():152381. PubMed ID: 38306813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.
    Toupin-April K; Décary S; de Wit M; Meara A; Barton JL; Fraenkel L; Li LC; Brooks P; Shea B; Stacey D; Légaré F; Lydiatt A; Hofstetter C; Proulx L; Christensen R; Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Guillemin F; Beaton D; El-Miedany Y; Mittoo S; Westrich Robertson T; Bartlett SJ; Singh JA; Mannion M; Nasef SI; de Souza S; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Carrott D; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Umaefulam V; Monti S; Melburn C; Abaza N; Schultz K; Stones S; Kiwalkar S; Srinivasalu H; Constien D; King LK; Tugwell P
    Semin Arthritis Rheum; 2021 Jun; 51(3):593-600. PubMed ID: 33892937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protocol for the development of a core outcome set for lateral elbow tendinopathy (COS-LET).
    Bateman M; Evans JP; Vuvan V; Jones V; Watts AC; Phadnis J; Bisset L; Vicenzino B
    Trials; 2021 May; 22(1):339. PubMed ID: 33971941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer.
    Beyer K; MacLennan SJ; Moris L; Lardas M; Mastris K; Hooker G; Greene R; Briers E; Omar MI; Healey J; Tripathee S; Gandaglia G; Venderbos LDF; Smith EJ; Bjorkqvist J; Asiimwe A; Huber J; Roobol MJ; Zong J; Bjartell A; N'Dow J; Briganti A; MacLennan S; Van Hemelrijck M; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Eur Urol Focus; 2021 Sep; 7(5):943-946. PubMed ID: 34602368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A survey of knowledge, perceptions and use of core outcome sets among clinical trialists.
    Bellucci C; Hughes K; Toomey E; Williamson PR; Matvienko-Sikar K
    Trials; 2021 Dec; 22(1):937. PubMed ID: 34924001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Navigating the path of progress: The OMERACT 2023 emerging leaders program.
    Campbell TM; Finzel S; Siddle H; Christensen R; Nielsen SM; Najm A; Otobo TM; Sahbudin I; Sinnathurai P; Stok KS; Touma Z; April KT; Grosskleg S; Tugwell P; Richards B
    Semin Arthritis Rheum; 2024 Jun; 66():152414. PubMed ID: 38447468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome measures in rheumatology applied in self-management interventions targeting people with inflammatory Arthritis A systematic review of outcome domains and measurement instruments.
    Hansen CW; Esbensen BA; de Thurah A; Christensen R; de Wit M; Cromhout PF
    Semin Arthritis Rheum; 2022 Jun; 54():151995. PubMed ID: 35397237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.
    Jacobson ME; Thomas KS; Apfelbacher CJ; Leshem YA; Williams HC; Gerbens LAA; Spuls PI; Schmitt J; Howells L; Katoh N; Simpson EL;
    Arch Dermatol Res; 2023 Nov; 315(9):2617-2622. PubMed ID: 37432466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development Methodology, Availability, and Implementation of Core Outcome Sets in Pediatric Surgery.
    Allin BSR; Bethell GS; Hall NJ
    Eur J Pediatr Surg; 2024 Apr; 34(2):128-136. PubMed ID: 37871644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.